喀麦隆按照SIOP-PODC低收入地区推荐方案治疗视网膜母细胞瘤的结局
该研究在喀麦隆两家浸信会医院纳入2012至2016年诊断的82例视网膜母细胞瘤患儿,按国际视网膜母细胞瘤分期系统分期,依照SIOP-PODC低收入国家指南给予局部治疗联合长春新碱、环磷酰胺、多柔比星方案化疗,伴或不伴手术,终点为24个月生存。结果显示24个月总生存率50.0%,局限期患儿为68.8%,估计累积生存率0.528(标准误0.056),分期与总生存显著相关(p<.001)。死亡原因以疾病进展或复发(60.5%)和中性粒细胞减少性脓毒症(15.9%)为主。作者认为该结果证明了SIOP-PODC推荐方案在中低收入地区治疗视网膜母细胞瘤的有效性和可行性。
要点
- 82例患儿24个月总生存率50.0%,局限期患儿24个月生存率68.8%。
- 分期与总生存显著相关(p<.001),为影响生存的最重要因素。
- 死亡原因中疾病进展/复发占60.5%,中性粒细胞减少性脓毒症占15.9%。
- 按SIOP-PODC低收入国家指南给予局部治疗联合长春新碱、环磷酰胺、多柔比星化疗,伴或不伴手术。
- 24个月估计累积生存率为0.528(标准误0.056)。
适用人群与场景
- 2012至2016年在喀麦隆两家浸信会医院诊断的视网膜母细胞瘤患儿,共82例;单侧病变占79.3%,男性占61.0%,中位年龄24个月(范围1-112个月,标准差19)。
诊断标准与关键阈值
- 采用国际视网膜母细胞瘤分期系统进行分期:局限期占58.5%,转移期占35.4%,分期未知占6.1%。
处置流程与药物剂量
- 按SIOP-PODC低收入国家指南,治疗包括局部治疗和联合化疗(长春新碱、环磷酰胺、多柔比星),伴或不伴手术。
研究设计与关键结果
- 纳入82例患儿,24个月总生存率50.0%,局限期患儿24个月生存率68.8%。
- 24个月估计累积生存率为0.528(标准误0.056)。
- 分期与总生存显著相关(p<.001)。
- 死亡原因:疾病进展/复发60.5%,中性粒细胞减少性脓毒症15.9%,不明原因18.4%,无关感染2.6%,术后死亡2.6%。
证据类型、等级与局限
- 证据类型:基于SIOP-PODC低收入地区推荐方案的单臂治疗结局报告(指南实施性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,SIOP-PODC提出的视网膜母细胞瘤管理指南在中低收入地区具有有效性和可行性。
- 分期是影响总生存的最重要因素,局限期患儿24个月生存率(68.8%)高于总体(50.0%)。
指南或共识出处
- SIOP-PODC(国际儿科肿瘤学会-发展中国家儿科肿瘤学组)低收入国家视网膜母细胞瘤治疗推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The International Society of Paediatric Oncology-Paediatric Oncology in Developing Countries (SIOP-PODC) group recommended graduated-intensity retinoblastoma treatment for children in low- and middle-income countries with limited local resources.
AIM: The aim was to improve outcome of children with retinoblastoma by means of a treatment protocol for low-income settings as recommended by the SIOP-PODC recommendation in Cameroon.
METHODS: Children diagnosed with retinoblastoma between 2012 and 2016 were treated in two Baptist Mission hospitals in Cameroon, staging according to the International Retinoblastoma Staging System. Treatment included local therapy and combination chemotherapy (vincristine, cyclophosphamide, and doxorubicin) with or without surgery as per SIOP-PODC guidelines for low-income countries. Endpoint was survival at 24 months. Kaplan-Meier curves with log-rank (Mantel-Cox) chi-square (χ2 ) with respective p-values were prepared.
RESULTS: Eighty-two children were included, of whom 79.3% had unilateral disease. The majority were males (61.0%) with median age 24 months (range 1-112 months; standard deviation [SD] 19). Limited disease was diagnosed in 58.5%, metastatic disease in 35.4%, and unknown stage in 6.1%. Overall survival (OS) was 50.0% at 24 months post diagnosis, but 68.8% for limited disease. Estimated cumulative survival at 24 months was 0.528 (standard error [SE] 0.056). Causes of death included disease progression/relapses (60.5%), neutropenic sepsis (15.9%), unknown causes (18.4%), unrelated infection (2.6%), and death post surgery (2.6%). Stage was significantly associated with OS (p < .001).
CONCLUSION: Stage was the most significant factor for good OS and demonstrated the efficacy and feasibility of the SIOP-PODC-proposed management guidelines for retinoblastoma in a lower middle-income setting.
参考来源
- Kruger M, van Elsland SL, Afungchwi GM, et al. Outcome of retinoblastoma treatment protocol in Cameroon as per SIOP-PODC recommendation for a low-income setting. Pediatr Blood Cancer. 2022. PMID: 35403812. doi:10.1002/pbc.29642
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。